check and action the test results, following dose reductions, following guidance. Chemotherapy is prescribed prior receiving the genetic report in 10 CPT. 6 hospitals would delay administration when result is missing.
Conclusion and RelevanceThere is a rich multidisciplinary involvement in checking the results of the test, including making the correct dose adjustments. The use of DPYD tests to prevent chemotherapy toxicity follows a safe and robust pathway within our region.
REFERENCES AND/OR ACKNOWLEDGEMENTS[i] UK Chemotherapy Board, 'Personalised Medicine Approach For Fluoropyrimidinebased Therapies,' 2020. [Online]. Available: https://www.theacp.org.uk/userfiles/file/ resources/dpd-testing-ukcb-july-2020-updated.pdf [ii] EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine | European Medicines Agency (europa.eu) [iii] 5-fluorouracil (intravenous), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at increased risk of severe and fatal toxicity -GOV.UK (www.gov.uk) [iv] Nijjar R, Shaunak N, Mahmoud S, Thwaites B, Desai M, Ajediti C, Brown A, Yeoh I, Patel T, Masento S. 'A collaborative audit on DPYD testing of all patients initiated on fluoropyrimidines (5-fluorouracil, capecitabine and oral prodrug tegafur) across 5 London teaching hospitals
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.